We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Read MoreHide Full Article
Eli Lilly and Company’s (LLY - Free Report) shares are up almost 4% following a positive FDA panel recommendation for its type II diabetes drug, Jardiance (SGLT-2 inhibitor). Lilly and its partner, Boehringer Ingelheim, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular (CV) risk reduction.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee met to review the data and voted 12-11 that enough evidence exists to establish that Jardiance reduces CV death in adults with type 2 diabetes and established CV disease.
While the FDA usually follows the advice of its advisory panel, it is not required to do so. Considering the vote in favor of label expansion was so close, concerns remain that the FDA might ask for another study.
However, inclusion of this data in the label would be a huge boost for Lilly. With about 50% of deaths in type II diabetics resulting from CV disease, the addition of this data to Jardiance’s label would lead to a major surge in sales.
Meanwhile, earlier this year, Lilly and Boehringer had announced plans to conduct two outcome studies investigating Jardiance for the treatment of people with chronic heart failure. The studies are scheduled to begin by next April and will be conducted in patients with chronic heart failure both with and without type II diabetes.
While the diabetes market holds immense commercial potential, it is pretty crowded given the presence of companies like Novo Nordisk A/S (NVO - Free Report) , Johnson & Johnson (JNJ - Free Report) and Merck & Co. Inc. (MRK - Free Report) among others.
Lilly is a Zacks Rank #3 (Hold) stock. Johnson & Johnson is a better-ranked stock in the large-cap pharma sector with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Eli Lilly Stock Up on FDA Advisory Panel Vote for Jardiance
Eli Lilly and Company’s (LLY - Free Report) shares are up almost 4% following a positive FDA panel recommendation for its type II diabetes drug, Jardiance (SGLT-2 inhibitor). Lilly and its partner, Boehringer Ingelheim, are seeking FDA approval for the inclusion of data from the EMPA-REG OUTCOME study, which showed cardiovascular (CV) risk reduction.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee met to review the data and voted 12-11 that enough evidence exists to establish that Jardiance reduces CV death in adults with type 2 diabetes and established CV disease.
While the FDA usually follows the advice of its advisory panel, it is not required to do so. Considering the vote in favor of label expansion was so close, concerns remain that the FDA might ask for another study.
However, inclusion of this data in the label would be a huge boost for Lilly. With about 50% of deaths in type II diabetics resulting from CV disease, the addition of this data to Jardiance’s label would lead to a major surge in sales.
Meanwhile, earlier this year, Lilly and Boehringer had announced plans to conduct two outcome studies investigating Jardiance for the treatment of people with chronic heart failure. The studies are scheduled to begin by next April and will be conducted in patients with chronic heart failure both with and without type II diabetes.
While the diabetes market holds immense commercial potential, it is pretty crowded given the presence of companies like Novo Nordisk A/S (NVO - Free Report) , Johnson & Johnson (JNJ - Free Report) and Merck & Co. Inc. (MRK - Free Report) among others.
Lilly is a Zacks Rank #3 (Hold) stock. Johnson & Johnson is a better-ranked stock in the large-cap pharma sector with a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>